177Lu-DOTATATE for the Treatment of Stage IV or Recurrent Breast Cancer
177Lu-DOTATATE for the Treatment of Stage IV or Recurrent Breast Cancer
Recruiting · NCT04529044 · Registry updated 2026-06-05Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| 177Lu-DOTATATE for the Treatment of Stage IV or Recurrent Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder | Recruiting | Phase 2 | 2026-06-05 | NCT04529044 |
4 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Advanced Accelerator Applications | 11 |
| Novartis Pharmaceuticals | 432 |
| OHSU Knight Cancer Institute | 61 |
| Oregon Health and Science University | 244 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| OHSU Knight Cancer Institute | Portland | United States | 69 |